Applied Genetic Technologies

Applied Genetics Technologies Corporation (AGTC) is developing therapies designed to transform the lives of patients with severe diseases, offering hope to patients with unmet medical needs. With a highly specialized team of physicians and researchers, They use cutting-edge techniques to develop treatments for patients that have diseases caused by broken genes. They use gene therapy, which replaces those broken genes with normal functional genes, allowing a patient’s own body to produce proteins to treat their illness. A single injection provides long-lasting treatment, leading to a better quality of life for patients worldwide.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced that it has commenced an underwritten public offering of its common stock. All of the shares in the proposed offering are being sold by AGTC. In addition, AGTC expects to grant to the underwriter a 30-day option to purchase up to an additional 15% of shares of the common stock sold in the public offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

AGTC Announces Proposed Public Offering of Common Stock

Genetic Technologies

Applied Genetic Technologies' (AGTC) CEO Sue Washer on Q2 2022 Results - Earnings Call Transcript

-Company on track to provide 3-month interim SKYLINE trial results in 2Q 2022-

AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2021

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced that it will report financial results for the quarter ended December 31, 2021 before the market opens on Monday, February 14, 2022. AGTC management will host a conference call beginning at 8:00 AM Eastern Time on the same day to review the financial results and provide a corporate update.

AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 14, 2022

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced it had exceeded the enrollment target in the Company's SKYLINE trial of AGTC-501, a recombinant AAV vector-based gene therapy developed for the treatment of X-linked retinitis pigmentosa (XLRP). A total of 14 patients have been enrolled across the high and low dose groups, exceeding the planned target enrollment of 12.

AGTC Exceeds Enrollment Target in SKYLINE Trial of AGTC-501 for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

Robinson's expertise in development and commercialization adds to the clinical and commercial experience of newly appointed management team Robinson's expertise in development and commercialization adds to the clinical and commercial experience of newly appointed management team

AGTC Appoints Biopharmaceutical Industry Leader James Robinson to its Board of Directors

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced the appointment of Abraham Scaria, Ph.D., as Chief Science Officer.

AGTC Appoints Abraham Scaria, Ph.D., as Chief Science Officer

- Poster presentation highlights safety and efficacy potential of AGTC-501 as a treatment for X-linked retinitis pigmentosa (XLRP) - - Poster presentation highlights safety and efficacy potential of AGTC-501 as a treatment for X-linked retinitis pigmentosa (XLRP) -

AGTC Presents Data from Ongoing Phase 1/2 Trial of AGTC-501 at Upcoming American Academy of Ophthalmology 2021 Annual Meeting

Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q1 Fiscal Year 2022 Results - Earnings Call Transcript

Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of -14.29% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Applied Genetic Technologies (AGTC) Reports Q1 Loss, Lags Revenue Estimates

-Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2021 and 2022-

AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2021

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases, today announced that it will report financial results for the quarter ended September 30, 2021 before the market opens on Tuesday, November 9, 2021. AGTC management will host a conference call beginning at 8:00 AM Eastern Time on the same day to review the financial results and provide a corporate update.

AGTC to Host First Quarter Financial Results Conference Call and Webcast on November 9, 2021

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced Sue Washer, President and Chief Executive Officer of AGTC, will present at the Dry AMD Therapeutic Development Summit being held virtually October 19 – 21, 2021.

AGTC to Present at Upcoming Dry AMD Therapeutic Development Summit

- AGTC Welcomes Susan Schneider as the Chief Medical Officer and Sarah C. DiSalvatore as the Vice President of Clinical Operations - - AGTC Welcomes Susan Schneider as the Chief Medical Officer and Sarah C. DiSalvatore as the Vice President of Clinical Operations -

AGTC Announces Two Key Leadership Team Appointments

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced Sue Washer, President and Chief Executive Officer of AGTC, will present at the 2021 Cell & Gene Meeting on the Mesa being held October 12-14, 2021.

AGTC to Present at Upcoming Cell & Gene Meeting on the Mesa

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that Sue Washer, President and Chief Executive Officer of AGTC, will be participating in a fireside chat at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference at 1:20pm ET on Thursday, September 30th, 2021.

AGTC to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

After escalating the dose in its pediatric gene therapy trial, Applied Genetic Technologies Corporation (NASDAQ: AGTC) has run into safety problems.  The Company recently enrolled six pediatric achromatopsia (ACHM) with CNGB3 gene mutation and five pediatric ACHM patients with CNGA3 mutation in high dose groups 5a and 6a.

Kids Suffer Adverse Reactions In Applied Genetic's Color Blindness Gene Therapy Trial

Applied Genetic Technologies Corporation (AGTC) CEO Sue Washer on Q4 2021 Results - Earnings Call Transcript

-Data from ongoing clinical trials in XLRP and ACHM shows evidence of clinical activity and tolerability; multiple data readouts expected in 2021 and 2022-

AGTC Provides Financial Results for the Fourth Quarter and Year Ended June 30, 2021

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that it will report financial results for the quarter and year ended June 30, 2021 after the market closes on Thursday, September 23, 2021. AGTC management will host a conference call beginning at 4:30 PM Eastern Time on the same date to review results and provide a corporate update.

AGTC to Host Fourth Quarter and 2021 Fiscal Year End Financial Results Conference Call and Webcast on September 23, 2021

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management will be participating in a company presentation at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13th, 2021.

AGTC to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that management will be participating in a fireside chat at the 2021 Wells Fargo Virtual Healthcare Conference on September 10th, 2021 at 8:40am E.T.

AGTC to Present at the 2021 Wells Fargo Virtual Healthcare Conference

WINSTON SALEM, N.C., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Greater Gift of Winston Salem, a non-profit that celebrates participation in clinical trials today announced a partnership with Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company developing genetic therapies for the treatment of rare inherited retinal diseases (IRDs), and mobile vision provider 2020 On-site, a company involved in IRD clinical research and provides complimentary eye exams and facilitates the delivery of eyeglasses to students in need.

Greater Gift, AGTC, and 2020 On-site Partner To Honor & Celebrate Clinical Trial Participants and Provide Eye Exams to Underserved Children in the Local Community

- Program helps those living with Achromatopsia receive filtered glasses and contact lenses to qualify for bioptic driving-

AGTC Announces Sponsorship of Achroma Corp's No Roadblocks Program

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced the addition of Yehia Hashad, MD to its Board of Directors.

News for Applied Genetic Technologies Stock (AGTC)